Drug Safety Alerts

Attention (ALERT)!

Relenza (Zanamivir) for inhalation is available in the market for treatment or prevention of influenza!

Relenza (Zanamivir) for inhalation is available in the market. According to US-FDA, it may be used for treatment or prevention of influenza (A & B) in more than 7-year age and who are symptomatic not more than 2 days. Usual dose in outbreaks is 10mg (2 disks) once daily for 28days. Relenza is not recommended in patients having airway disease (Asthma etc.) as it may cause bronchospasm. It should be discontinued if bronchospasm or symptoms of allergy or neuropsychiatric event appears.

Drug Safety Alerts,

Provincial Drug Control Unit,

Primary & Secondary Healthcare Department,

Govt. of the Punjab